Literature DB >> 3960694

The place of quinolones in antibacterial therapy in hospitals.

R P Mouton.   

Abstract

A comparative evaluation is made on activity, resistance problems and side effects of nine quinolones. These data and the information on clinical experiences are used to outline the author's view on the present position of these compounds in treatment policies. The following indications seem appropriate: norfloxacin or pipemidic acid in lower urinary tract infection, secondary to nitrofurantoin and sulfonamides; one of the more active quinolones, like ciprofloxacin, in case of therapy failure or multiple resistance; application for gonorrhoea appears attractive, but data on long-term effects and resistance are needed; in antibacterial combinations for selective bowel decontamination. Comparative clinical trials are essential before other indications for quinolones in clinical policies can be defined.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3960694     DOI: 10.1007/bf01975485

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  40 in total

1.  Resistance to ciprofloxacin.

Authors:  S T Chapman; D C Speller; D S Reeves
Journal:  Lancet       Date:  1985-07-06       Impact factor: 79.321

2.  Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations.

Authors:  A L Barry; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

3.  Serum and sputum concentrations of enoxacin after single oral dosing in a clinical and bacteriological study.

Authors:  B I Davies; F P Maesen; J P Teengs
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

4.  Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy.

Authors:  C E Cox; J R Simmons
Journal:  South Med J       Date:  1982-05       Impact factor: 0.954

5.  In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii.

Authors:  J D Gay; D R DeYoung; G D Roberts
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

6.  In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents.

Authors:  R Wise; J M Andrews; G Danks
Journal:  J Antimicrob Chemother       Date:  1984-03       Impact factor: 5.790

7.  Open, prospective study of the clinical efficacy of ciprofloxacin.

Authors:  C A Ramirez; J L Bran; C R Mejia; J F Garcia
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

8.  Norfloxacin versus trimethoprim-sulfamethoxazole in the therapy of uncomplicated, community-acquired urinary tract infections.

Authors:  E J Goldstein; M L Alpert; B P Ginsberg
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

9.  Activities of new quinoline derivatives against genital pathogens.

Authors:  J Aznar; M C Caballero; M C Lozano; C de Miguel; J C Palomares; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  1985-01       Impact factor: 5.191

10.  Selective antimicrobial modulation of human microbial flora: infection prevention in patients with decreased host defense mechanisms by selective elimination of potentially pathogenic bacteria.

Authors:  H F Guiot; J W van der Meer; R van Furth
Journal:  J Infect Dis       Date:  1981-05       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.